Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS)

BACKGROUND: Alemtuzumab, a humanized monoclonal antibody directed against the cell surface glycoprotein CD52, is licensed in Europe since October 2013 as treatment for adult patients with active relapsing-remitting multiple sclerosis (RRMS). In three randomized, rater-blinded active comparator clini...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:BMC Neurol
Autores principales: Ziemssen, Tjalf, Engelmann, Ulrich, Jahn, Sigbert, Leptich, Alexandra, Kern, Raimar, Hassoun, Lina, Thomas, Katja
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4950609/
https://ncbi.nlm.nih.gov/pubmed/27430352
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-016-0629-9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares